CAMBRIDGE, Mass., October 31, 2022 /PRNewswire/ — Nuvalent, Inc. NUVLa clinical-stage biopharmaceutical company focused on developing products I agree targeted therapies for clinically proven kinase targets in cancer, today announced the pricing of its previously announced underwritten public offering of 6,865,672 Class A common shares at a public price of $33.50 per share. All shares are offered by Nuvalent. Gross proceeds for Nuvalent from the Offering, before the deduction of underwriting discounts, commissions and other offering costs, are expected to be approximately $230.0 million. The offer is expected to be closed November 3, 2022, subject to the fulfillment of customary closing conditions. In addition, the underwriters have a 30-day option to purchase up to an additional 1,029,850 Class A common shares at the public offering price, less underwriting discounts and commissions.
JP Morgan, Cowen, Piper Sandler and BMO Capital Markets are acting as joint book-running managers for the offering.
The shares are being offered by Nuvalent pursuant to a registration statement filed with the Securities and Exchange Commission (“SEC”) August 10, 2022and declared effective by the SEC on August 16, 2022. The offering is being made only by means of the prospectus and prospectus supplement, which form part of the registration statement. A preliminary prospectus supplement relating to and describing the offering terms has been filed with the SEC and is available free of charge at the SEC’s website at www.sec.gov. A final prospectus supplement relating to the offering will be filed with the SEC. Copies of the final prospectus supplement and accompanying prospectus, if available, may be obtained from: JP Morgan Securities LLC, Attention: Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, by phone at (866) 803-9204, or by email at prospectus-eq_fi@jpmchase.com; Cowen and Company, LLC…
